Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients

Transplantation

Volumn 91, Issue 2, 2011, Pages 237-244

  Luan, Fu L ^a   Kommareddi, Mallika ^a   Ojo, Akinlolu O ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Cost utility; Cytomegalovirus; Kidney transplantation; Preemptive therapy; Qualityadjusted life years; Universal prophylaxis

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; KIDNEY GRAFT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DECISION TREES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SEROLOGIC TESTS;

EID: 78751645097     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318200000c     Document Type: Article

References (39)

1. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(suppl 7): S754.
2. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
3. Abbott KC, Hypolite IO, Viola R, et al. Hospitalizations for cytomega-lovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402.
4. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovi-rus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
5. Lewis RM, Johnson PC, Golden D, et al. The adverse impact of cyto-megalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. Transplantation 1988; 45: 353.
6. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalo-virus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
7. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69.
8. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21: 309.
9. McCarthy JM, Karim MA, Krueger H, et al. The cost impact of cyto-megalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277.
10. Tsevat J, Snydman DR, Pauker SG, et al. Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 1991; 52: 259.
11. Johnson PC, Lewis RM, Golden DL, et al. The impact of cytomegalo-virus infectionon seronegative recipients ofseropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression. Transplantation 1988; 45: 116.
12. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
13. Cytomegalovirus. Am J Transplant 2004; 4(suppl 10): 51.
14. Kotton CN, Kumar D, Caliendo AM, AsbergA, ChouS, Snydman DR, Allen U, Humar A. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95.
15. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management ofcytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
16. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
17. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869.
18. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
19. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
20. Hoffmann TW, Halimi JM, Buchler M, et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomeg-alovirus infection after kidney transplantation. J Med Genet 2010; 47: 54.
21. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganci-clovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899.
22. McGillicuddy JW, Weimert NA, Taber DJ, et al. Can preemptive cyto-megalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation 2010; 89: 1218.
23. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York, Oxford University Press 1996.
24. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005; 294: 2618.
25. Helantera I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19: 893.
26. Tilden DP, Chapman J, Davey PJ, et al. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomega-lovirus infection and disease in renal transplantation. Clin Transplant 2004; 18: 312.
27. Legendre C, Beard SM, Crochard A, et al. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ 2005; 6: 172.
28. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
29. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allo-graft recipients. Transplantation 2000; 70: 1166.
30. Luan FL, Samaniego M, Kommareddi M, et al. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infect Dis 2010; 12: 473.
31. Reischig T, Jindra P, Hes O, et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87: 436.
32. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
33. Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: A cost utility analysis. Am J Kidney Dis 2007; 49: 801.
34. US Organ Procurement and Transplantation Network, the Scientific Registry of Transplant Recipients. 2008 Annual Report, Transplant Data 1994-2007. Department of Health and Human Service, Human Resource and Service Administration, Healthcare System Bureau, Division of Transplantation, Available at: http://optn.transplant.hrsa. gov/latestData, accessed September, 2009
35. National Institute of Health (NIH), (NIDDK) NIoDaDaKD. 2008 Annual data report: Atlas of end-stage renal disease in the United States. 2008.
36. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
37. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993; 13: 322.
38. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419.
39. Luan FL, Stuckey LJ, Park JM, et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 2449.